Understanding metal elements in radiation-induced mouth sores

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the correlation between metal elements and the occurrence of radiation-induced oral mucositis (RIOM) in patients undergoing radiotherapy for head and neck tumors. It aims to identify predictive factors that could help in anticipating the severity and incidence of RIOM, which significantly impacts patients' quality of life and treatment efficacy. By analyzing the steady-state of metallic elements in patients, the study seeks to explore effective prevention and treatment strategies for this common complication of radiotherapy. The findings could lead to improved management of RIOM and better overall outcomes for patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1）Sign the informed consent form; 2) Confirmed by pathological biopsy as nasopharyngeal carcinoma or head and neck tumors; 3) Have indications for radiotherapy and voluntarily accept radiotherapy; 4) ECOG PS: 0/1; 5) Age: 18-75 years old; 6) Laboratory tests confirm good organ function.

Exclusion Criteria:

1. There are contraindications for radiotherapy;
2. Combined with other tumors;
3. Pathological sections could not be obtained;
4. The patient has any serious concurrent diseases that may pose unacceptable risks or have a negative impact on trial compliance. For instance, unstable heart diseases requiring treatment, chronic hepatitis, kidney diseases with poor conditions, uncontrolled diabetes (fasting blood glucose greater than 1.5 × ULN), and mental disorders;
5. The researcher judged that it was not suitable to participate in this study.

Where it's running

• Nanfang hospital, Southern medical university
  Guangzhou, Guangdong, China Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using breath analysis to predict mouth sores from radiotherapy in head and neck cancer patients

  This study is testing whether analyzing breath samples can help predict mouth sores in head and neck cancer patients receiving radiotherapy.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT06767488

• SI-B036 in head and neck and other solid tumors: a first-in-human study

  This early-phase study tests SI-B036 in adults with locally advanced or metastatic head and neck cancers and other solid tumors to see if it is safe and tolerable, and to get initial clues about its activity.

  Recruiting at 2 sites Phase 1 Sichuan Baili Pharmaceutical Co., Ltd. · Changsha, Hunan and 1 other locations · NCT07763639

• LRRC15-targeted PET imaging for more precise diagnosis and staging of pancreatic, breast, lung, sarcoma and head-and-neck cancers

  This project tests whether an LRRC15-targeted PET scan can better detect and stage LRRC15-expressing cancers and measures how the tracer behaves in healthy adults.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07552467

• Traditional Chinese oral solution and mouthwash to shorten severe radiation-induced mouth sores in head and neck cancer.

  This trial will try a combined traditional Chinese oral solution and mouthwash to shorten and ease severe radiation-induced mouth sores in adults receiving radiotherapy for head and neck cancer.

  Recruiting Phase 2 West China Hospital · Chengdu, Sichuan · NCT07339774

• Understanding how mutant p53/YAP proteins affect treatment resistance in head and neck cancer

  This study looks at how changes in certain proteins in head and neck cancer cells might make them resistant to treatment, helping doctors find better ways to fight the disease.

  Recruiting Regina Elena Cancer Institute · Roma, Rome · NCT06791941

• Targeted alpha therapy [212Pb]VMT-Alpha-NET for SSTR-positive metastatic or inoperable GI neuroendocrine, pheochromocytoma/paraganglioma, small cell lung, kidney, and head & neck cancers

  This trial will try an experimental targeted alpha-particle drug called [212Pb]VMT-Alpha-NET in adults whose metastatic or inoperable tumors show somatostatin receptor (SSTR) expression.

  Recruiting Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT06479811

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.